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A bstract
Th e p resen t s tudy  w as carried  o u t to  exam in e 
the m echanism s of the synergistic in teraction  o f 
P A F  and  A 23187  m ed ia ted  p la te le t agg reg ation . 
W e found  that p la te le t aggregation  m ed iated  by  
sub thresho ld  concentrations o f P A F  (5  nM ) and  
A 23187  (1  µM ) w as  inh ib ited  by  P A F  recep tor 
b lo cker (W E B  2086 , IC 50 = 0 .65  µM ) and  ca lc iu m  
channe l b lockers , d iltiazem  (IC 50 = 13  µM ) and  
verapam il (IC 50 = 18  µM ). P retreatm ent o f p la te -
le ts  w ith  P A F  an d  A 23187 ind uced  rise  in  in -
trace llu la r ca lc ium  an d  th is  e ffec t w as  a lso  
b locked  by  verapam il. W h ile  exam in ing  the  ro le  
o f the  d ow n stream  s ig na ling  pa th w ays , w e  
foun d  th at p la te le t ag gregatio n  in duced  by  the  
co -ad d ition  o f P A F  an d  A 23187 w as  a lso  inh i-
b ited  by  low  concentrations o f phospholipase C  
(P LC ) inh ib ito r (U 73122; IC 50 =  10  µM ), a  cyc lo -
oxygenase inhibitor (indom ethacin; IC 50 = 0.2 µM ) 
and  inh ib ito r o f T LC K , h erb im yc in  A  w ith  IC 50 
va lue  o f 5  µM . The e ffec t w as  a lso  in h ib ited  by  
a  sp ec ific  T X A 2 recep tor an tag on is t, S Q  29548  
w ith  very  lo w  IC 50 va lue  o f 0 .05  µM . H ow ever, 
the inhib itors of M A P kinase, PD 98059 and pro -
tein kinase C, chelerythrine had no effect on PAF  
and A 23187-ind uced  p la te le t agg reg ation . These 
da ta  sug gest tha t the  syn erg ism  b etw een  P A F  
and A23187 in platelet aggregation involves activa-
tion of thromboxane and tyrosine kinase pathways.
Keyw ords: calcium ionophore A23187; platelet activat-
ing factor; platelet aggregation; thromboxane tyrosine 
kinase
In troduction
A number of platelet agonists such as epinephrine, 
5-HT, ADP, and platelet activating factor (PAF) act 
synergistically in platelet aggregation and up to date, 
few studies have been carried out in human platelets 
on the cooperative effects of PAF and calcium ion-
ophore A23187. It is well documented that most of 
the platelet agonists act largely through the stimula-
tion of G-protein coupled receptors (GPCRs).
  PAF, a phospholipid mediator, is a very strong 
platelet activator and human platelets show high 
affinity binding sites for this agonist. It also induces 
adhesion of platelets to the endothelium in the pre-
sence of activated leukocytes (Hirafuji and Shinoda, 
1991). PAF is also known to play an important role 
in various pathophysiological conditions that include 
modulation of blood pressure, hypotension, cardiac 
dysfunction, cardiac anaphylaxis, hemorrhagic, trau-
matic and septic shock syndromes (Anderson et al., 
1991; Montrucchio et al., 2000). Because of its ability 
to stimulate endothelial migration and angiogenesis, 
a potential role of PAF is also known as a potent 
stimulator of thromboxane A2 (TXA2) production in 
human platelets (Shah et al., 2001). It is reported that 
PAF acts through the stimulation of pertussis toxin 
insensitive G-proteins (Gq/11) resulting in the stimula-
tion of phospholipase C (PLC) and thus generation 
of second messenger diacylglycerol (DAG) and ino-
sitol-1, 4,5-triphosphate (IP3), which results in the 
activation of protein kinase C (PKC) and the mobili-
zation of intracellular Ca2+, respectively (Obberghen- 
Schilling and Pouyssegur, 1993). Both Ca2+ and PKC 
stimulate platelet aggregation and also elicit syner-
gism in platelets (Crabos et al., 1992). Consistent with 
the potential involvement of Gq/PLC pathway, the 
deficiency of Gq protein in transgenic mice leads to 
impairment of agonist-induced platelet aggregation 
(Offermanns et al., 1997).
  In platelets, calcium plays a pivotal role in platelet 
aggregation (Heemskerk and Sage, 1994). An in-
crease in cytoplasmic Ca2+ can be brought about by 
either enhanced Ca2+ influx from the external medium 
or release from internal stores (Berridge, 1993). Ca2+ 
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ionophores, such as A23187, induce platelet aggre-
gation. It stimulates the procoagulant activity of cells, 
which is thought to be mediated by scrambling of the 
plasma membrane phospholipids. This results in the 
exposure of phosphatidyl inositol serine and other 
negatively charged phospholipids in the outer leaflet 
of the plasma membrane (Williamson et al., 1995).
  In addition, PAF also stimulates TXA2 production 
in human platelets. It enhances vasoconstriction of 
the coronary arterioles (DeFily et al., 1996) and at 
the inflammatory coronary lesions in vivo by itself as 
well as in a synergistic manner with other agonists 
like epinephrine and 5-HT (Shah et al., 2000; Saeed 
and Rasheed, 2003). Because of the close interaction 
between many agonists and their importance in 
thrombosis, hypertension and atheroscelrosis, this 
study was conducted to examine the synergism bet-
ween PAF and A23187 to elucidate the possible signal-
ing mechanism(s) involved during this synergism.
M ateria ls and M ethods
C hem icals
PAF, calcium ionophore, A23187, diltiazem, verapa-
mil, herbimycin A, U73122, PD98059 and cheler-
ythrine all were purchased from the Sigma Chemical 
Co. (St. Louis, Mo). All other chemicals used were 
of the highest purity grade available.
Preparation of hum an p latelets
Blood was taken by vein-puncture from normal human 
volunteers reported to be free of medications for one 
week. Blood samples were mixed with 3.8% (w/v) 
sodium citrate solution (9:1) and centrifuged at 260 
g for 15 min at 20oC to obtain platelet rich plasma 
(PRP). Platelet count was determined by phase con-
trast microscopy and all aggregation studies were 
carried out at 37oC with PRP having platelet counts 
between 2.5 and 3.0×108 ml-1 of plasma (Shah and 
Saeed, 1995).
M easurem ent of p latelet aggregation
Aggregation was monitored using Dual-channel Lumi- 
aggregometer (Model 400 Chronolog Corporation, 
Chicago, IL) using 0.45 ml aliquots of PRP. The final 
volume was made up to 0.5 ml with the test drug 
dissolved either in normal saline or appropriate ve-
hicle known to be devoid of any effect on aggrega-
tion. Aggregation was induced with PAF and A23187 
and their sub-threshold concentrations were deter-
mined. To obtain the synergistic effect of PAF and 
A23187, we added low concentrations of these 
agonists. The anti-aggregatory effects of different 
compounds were studied by pretreatment of PRP with 
various inhibitors for one min followed by addition of 
the sub-threshold concentrations of PAF (5 nM) and 
A23187 (1 µM). The resulting aggregation was re-
corded for 5 min after challenge by the change in 
light transmission as a function of time. Once the 
anti-platelet activity of various inhibitors against these 
agonists was established, dose-response curves were 
constructed to calculate the IC50 values of inhibitors. 
Throm boxane form ation  in  p latelets
Arachidonic acid metabolism and TXA2 formation were 
studied with the co-addition of PAF (5 nM) and 
A23187 (1 µM) using radiochemical methods (Shah 
et al., 2000). For these studies, human blood platelets 
were routinely obtained in plastic bags containing 
30-40 ml of concentrated PRP from The Aga Khan 
University Hospital Clinical Laboratory, Karachi. The 
PRP was centrifuged at 1,200 g for 20 min and the 
sedimented platelets were washed twice with an 
ice-cold phosphate buffer (50 mM, pH 7.4) containing 
sodium chloride (0.15 M) and EDTA (0.2 mM). After 
centrifugation, washed platelets were resuspended in 
the same buffer without EDTA and homogenized at 
4oC using a polytron homogenizer for 15 s. The 
homogenate was centrifuged at 1,200 g for 20 min 
and 300 µl of the supernatant (containing 0.4 mg of 
protein) was incubated with 10 µg unlabelled ara-
chidonic acid (AA) and 0.1 µCi [1-14C]-arachidonic 
acid in the presence and absence of the agonists. 
After 15 min of gentle shaking in air at 37oC, the 
reaction was stopped by adding 0.4 ml of citric acid 
(0.4 M) and ethyl acetate (7.0 ml). After mixing and 
centrifuging at 600 g for 5 min at 4oC, the organic 
layer was separated and evaporated to dryness under 
nitrogen. Residues were dissolved in 40 µl ethanol 
and 20 µ l were applied to silica gel G thin layer 
chromatography (TLC) plates (Analtech, Delaware). 
The solvent system used for the separation of TXB2 
in dried organic extracts of platelet incubates as 
above was ethyl acetate: isooctane: water and acetic 
acid (11:5:10:2, v/v, upper phase). Radioactive zones 
were located and quantified by use of a Berthold 
T.L.C. linear analyzer and chromatography data sys-
tem (Model LKB 511, Berthold, W. Germany). Protein 
concentration was determined using human serum 
albumin as standard (Lowry et al., 1951).
M easurem ent of C a2+ Influx  
The agonist-induced influx of Ca2+ was measured 
using Fura-2 AM (Saeed et al., 1997). Platelets (1× 
108/m l) were suspended in Ca2+-free standard 
medium (NaCl 145 mM, KCl 5 mM/L, MgCl2 1 mM/L, 
HEPES 10 mM, glucose 10 mM, pH 7.4). Fura-2 AM 
dissolved in DMSO was added to the platelet sus-
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pension at 37oC for 45 min. The platelet suspension 
was centrifuged at 350 g for 15 min and the platelet 
pellet resuspended in fresh standard medium. Fura- 
2AM fluorescence was monitored at 340 nm and 505 
nm (excitation and emission, respectively) in platelets 
treated with PAF (5 nM) and A23187 (1 µM). 
D ata analysis
IC50 is the concentration (µM) producing 50% inhi-
bition of platelet aggregation (control response taken 
as 100%). The 50% inhibitory concentration (IC50) 
values were calculated as means ± SEM of 5-7 
independent experiments. Differences between control 
and test measurements were assessed by student's 
t-test.
R esu lts
The results demonstrated that treatment of PRP with 
PAF (5-800 nM) and A23187 (1 µM) showed concen-
tration-dependent increase in platelet aggregation. 
However, simultaneous addition of subthreshold con-
centrations of PAF (5 nM) and A23187 (1 µM) ex-
hibited a synergistic effect (Figure 1A). Such an effect 
was comparable to that obtained by higher con-
centrations of PAF (800 nM) or A23187 (10 µM) 
alone. The synergism between PAF and A23187 was 
inhibited by pre-treatment of PRP with a potent PAF 
antagonist, WEB 2086 (IC50 = 0.65 µM) (Figure 1B) 
F ig u re  1 . (A) Tracings from representative experiments showing synergism of PAF (5 nM) and A23187 (1 µM). The synergistic
effect of PAF and A23187 on platelet aggregation is blocked by (B) W EB 2086, a PAF receptor antagonist, (C) U73122, a 
phospholipase C inhibitor and (D) diltiazem, a calcium channel blocker. Inhibitors were added one minute before the agonists.
Control means platelet aggregation induced by PAF (5 nM) and A23187 (1 µM). n = 5.
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Tab le  1 . The effect of various inhibitors on subthreshold concentration
of platelet activating factor (5 nM) and A23187 (1 µM) induced platelet
aggregation.
ꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚꠚ
   Inhibitors Mean IC50 µM ± SEM
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
W EB 2086 0.65 ± 0.04
Diltiazem 13 ± 2.3
Verapamil 18 ± 3.2
U73122 10 ± 0.7
Indomethacin  0.2 ± 0.03
SQ 29548  0.05 ± 0.001
Herbimycin A  5 ± 0.8
PD98056 NE
Chelerythrine NE
ꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏꠏ
Data is mean ± SEM (n = 5-7) and is indicated as half-maximal effect
(IC50) of the inhibitors. NE, No effect.
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indicating that the effect is receptor mediated. We 
used PLC inhibitor; U73122 to examine if PAF and 
A23187 mediated effects involved the activation of 
PLC. Results show that pretreatment of PRP with 
U73122 completely inhibited the synergistic effect of 
PAF and A23187 with an IC50 of 10 µM (Figure 1C). 
We also tested the effect of Ca2+ channel blockers 
on platelet aggregation and found that the synergistic 
effect of PAF and A23187 was inhibited by both 
verapamil and diltiazem (Figure 1D) with IC50 values 
of 18 and 13 µM respectively. 
  Similar inhibitory effect of verapamil was also ob-
tained using Fura-2 AM assay for the measurement 
of Ca2+ release as shown in Figure 2. To determine 
the role of cyclooxygenase, we used indomethacin 
(Figure 3A) which inhibited PAF and A23187 induced 
aggregation with IC50 value of 0.2 µM while, SQ 
29548 a specific TXA2 receptor antagonist also in-
hibited platelet aggregation with IC50 value of 0.05 µM 
(Figure 3B). Both PAF and A23187 in subthreshold 
concentrations also stimulated TXA2 formation in 
platelets up to many folds (Figure 4). The results of 
SQ, 29548 and TXA2 stimulation clearly explain the 
involvement of thromboxane/COX pathway in PAF 
and A23187 induced platelet aggregation. 
  Herbimycin A, a specific inhibitor of tyrosine kinase 
also inhibited PAF and A23187-induced aggregation 
with IC50 of 5 µM indicating the involvement of tyro-
sine kinase in this cascade (Figure 5).
  As stimulation of the G-protein/Ca2+ cascade leads 
to mitogen activated protein (MAP) kinase signaling 
(Heemskerk and Sage, 1994), we used the selective 
MEK inhibitor PD98059 against PAF and A23187 
synergism. Results show that pretreatment of PRP 
with PD98059 did not show any inhibitory effect on 
platelet aggregation by co-addition of subthreshold 
concentration of PAF and A23187. Similarly, the 
inhibitor of protein kinase C (chelerythrine; 20 µM) 
had no effect. 
F ig u re  4 . Effects of subthershold concentrations of PAF and A23187
on thromboxane A2 (TXA2) formation in human platelets. n = 6.
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F ig u re  2 . Effect of verapamil on PAF (5 nM) and A23187 (1 µM) 
induced rise in intracellular calcium [Ca2+]. Platelets were loaded with
Fura-2 AM and assays done as described in Materials and Methods.
Control represents unstimulated platelets and is taken as 100% . n =
6. Mean ± SEM.
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F ig u re  3 . (A) Concentration-dependent effects of cyclooxygenase 
inhibitor, indomethacin and (B) TXA2 receptor antagonist, SQ 29,548 
on platelet aggregation induced by co-addition of PAF and A23187.
Control means platelet aggregation induced by PAF (5 nM) and 
A23187 (1 µM). n = 7.
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D iscussion
In human platelets PAF causes the stimulation of Gq 
proteins by binding with specific transmembrane PAF 
receptors. The second messengers, Ca2+ and PKC 
generated in response to Gq/PLC activation bring 
about coordinated changes leading towards platelet 
aggregation (Crabos et al., 1992; Heemskerk and 
Sage, 1994). This indicates that both PAF and Ca2+ 
play a pivotal role in aggregation. Similarly our study 
shows that both PAF and A23187 in subthershold 
concentrations show synergism when used exogen-
ously. While studying mechanism of PAF and A23187 
mediated aggregation we found that different inhi-
bitors exhibited variable response against the syner-
gism. 
  Our data show that WEB2086, a PAF receptor 
antagonist inhibited PAF and A23187 induced aggre-
gation at very low IC50 values showing that the effect 
is receptor mediated. 
  PAF causes the stimulation of Gq protein followed 
by the activation of PLC. This explains why U73122, 
a selective inhibitor of PLC, shows strong inhibitory 
effects as platelet aggregation induced by co-activa-
tion of these agonists. Further support in favour of 
Gq/PLC pathways is provided by the recent studies 
in transgenic mice where it is shown that Gq protein 
deficient mice lacked the ability of platelet aggregation 
(Offermanns et al., 1997). Some of the investigators 
reported that platelets lack L-type voltage dependent 
calcium channels but contain receptors operated 
calcium channels. The antiplatelet effects of calcium 
antagonists have been extensively studied in vitro, but 
such studies may involve high concentrations of the 
drugs. Verapamil is well-documented calcium ant-
agonist with regard to antiplatelet effects having the 
most varied possible mechanisms of action (Hjemdahl 
and Wallen, 1997). Our previous studies show that 
synergistic effect of various platelet agonists is 
blocked by calcium-channel blockers, verapamil and 
diltiazem in very low concentration (Saeed et al., 
1997; Shah et al., 1999; Saeed et al., 2003). Similarly 
the present findings also show that PAF and A23187 
mediated platelet aggregation is also blocked by low 
concentration of verapamil or diltiazem. It is also 
supported by other studies that calcium channel 
blockers inhibit platelet activation induced by various 
agonists through different intracellular mechanisms 
(Valone, 1987). 
  Results with the channel blockers are consistent 
with the enduring proposal that calcium influx causes 
aggregation (Ware et al., 1986; Vinge et al., 1988). 
The increase in cytosolic Ca2+ causes activation of 
PLA2 and stimulation of COX activity, thus TXA2 
formation (Heemskerk and Sage, 1994).
  COX catalyzes the stepwise conversion of AA into 
reactive intermediates PGG2 and PGH2, which are the 
precursors of prostaglandins, prostacyclin and thromb-
oxanes (prostanoids). COX-1 is mainly present in 
platelets and in other tissues (Piomelli, 1993). Num-
erous studies have shown that inhibitors of COX 
mainly belonging to the group of non-steroidal anti- 
inflammatory drugs (NSAIDs) also inhibit platelet 
aggregation by inhibiting TXA2 biosynthesis. TXA2 in 
an antocrine fashion binds with TXA2 receptors 
coupled with Gq protein and stimulate PLC and 
further enhance platelet aggregation. MAP kinase is 
one of the down stream signaling molecules involved 
in platelet aggregation (Shah et al., 2000). That can 
cultivate both Gq and G i-protein linked pathways 
(Della Rocca, et al., 1999). 
  Many studies show that activation of platelets by 
some agonists increase the level of tyrosine phos-
phorylation resulting in the appearance of a new set 
of tyrosine-phosphorylated proteins (Ferrel and Martin, 
1988; Golden and Yamamura, 1989). Increase in the 
phosphorylation of tyrosine residues is an early event 
in the signal transduction pathway for stimulation of 
platelets by PAF (Animesh et al., 1990). To investi-
gate the involvement of tyrosine kinase in present 
study we used herbimycin A, a known and specific 
inhibitor of tyrosine kinase which block PAF and 
A23187-induced aggregation in a concentration- de-
pendent manner (IC50 = 15 µM) showing that the 
synergism may also be due to the  TLCK activation.
  We found that MAPK inhibitor; PD98059 did not 
exhibit any inhibitory effect showing that MAP kinase 
pathway was inactive in PAF and A23187 mediated 
aggregation. However the role of PKC in the present 
study was changed as PKC inhibition had no effect 
on the synergism of PAF and A23187 in platelets In 
conclusion, our study show that the synergistic in-
teraction of PAF and A23187 in human platelet 
aggregation seems to follow the activation of throm-
boxane and tyrosine kinase pathways.
F ig u re  5 . Dose-response curve of specific tyrosine kinase inhibitor, 
herbimycin A on the synergistic interaction of subthreshold con-
centrations of PAF and A23187. n = 7
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